News for Towa Pharmaceutical Co., Ltd. (4553.T)

TOKYO, March 31, 2025 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and Welfare as a new drug, indicated for suppression of progression of dementia symptoms in mild to moderate Alzheimer's disease. The product is to be marketed as Rivaluen® LA Patch 25.92mg/51.84mg. It is the first extended-release Rivastigmine transdermal formulation approved for marketing in the country.

The global transdermal drug delivery system market revenue to reach USD 51.94 Billion by 2030....

Stock Market Quotes and News : Equities, Indexes, Commodities, Forex on MarketScreener.com

Stock Market Quotes and News : Equities, Indexes, Commodities, Forex on MarketScreener.com

Towa Pharmaceutical Receives Approval for Authorized Generic Version of Chugai's Osteoporosis Agent Edirol Chugai granted Towa... | December 3, 2021

/PRNewswire/ -- Le Luye Pharma Group (Luye Pharma) a annoncé aujourd'hui que sa filiale Luye Pharma Switzerland AG a conclu un accord avec Zambon Switzerland...

/PRNewswire/ -- Die Luye Pharma Group (Luye Pharma) gab heute bekannt, dass ihre Tochtergesellschaft Luye Pharma Switzerland AG eine Vereinbarung mit Zambon...